Abstract
According to data from the prethrombolytic era, a patient who survives a first myocardial infarction (MI) faces nearly an 80% chance of another cardiovascular disease (CVD) event within the next 5 yr (1). More contemporary data indicate that within 6 yr of an MI, approx 20% of men and 35% of women will sustain another heart attack with similar percentages developing congestive heart failure (CHF) (2). Thus, the diagnosis of an MI brings with it the high likelihood of recurrent cardiovascular events, compounding morbidity, and probable ultimate fatality. Viewed in this way, CVD is, in fact, much like many forms of cancer, although the reaction of many patients to those two diagnoses can be quite different. Perhaps this is related to antiquated notions, propagated at times by physicians, that mechanical cardiovascular therapies, such as bypass surgery and angioplasty, can “fix” the cardiovascular problem. The myriad of therapeutic options available to the cardiologist and their patients might further fuel such concepts. In reality, modern medicine might be better at “curing” some types of cancer than reversing advanced atherosclerosis. CVD patients suffer a chronic insidious disease that requires aggressive interventions to alter the complex process that led to its generation, propagation, and recurrence; steps untouched by acute mechanical treatments restoring patency or providing alternate paths of blood flow. Fortunately, the number of interventions, both medical and lifestyle, for so-called secondary prevention also continues to grow. Similarly, our understanding of atherogenesis and the development of acute coronary syndromes is also progressing, creating hope for the development of new, and perhaps more effective, therapeutic approaches. We are also left with the considerable challenge of applying those interventions known to reduce cardiovascular risk.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation 1982; 66: 401–414.
American Heart Association. 2001 Heart and Stroke Statistical Update. American Heart Association, Dallas, 2001.
Outcomes in WHI Trial of Estrogen, Progestin. Writing Group for the Women’s Health Initiative Investigators. JAMA 2002; 288: 321–333.
Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Control Clin Trials 1996; 17: 13–22.
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1–12.
Hilton TC, Chaitman BR. The prognosis in stable and unstable angina. Cardiol Clin 1991; 9: 27–38.
Rapaport E, Gheorghiade M. Pharmacologic therapies after myocardial infarction. Am J Med 1996; 101:4A61S–4A70S.
Grundy SM. Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. Postgrad Med 1997; 102: 81–90.
Brown BG, Zhao XQ, Bardsley J, Albers H. Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. J Intern Med 1997; 241: 283–294.
Furberg CD, Hennekens CH, Hulley SB, Manolio T, Psaty BM, Whelton PK. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 2. Clinical epidemiology: the conceptual basis for interpreting risk factors. J Am Coll Cardiol 1996; 27: 976–978.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Haffner, S. M. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease [editorial; comment]. Diabetes Care 1997; 20: 469–471.
Scandanavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see comments]. Lancet 1994; 344: 1383–1389.
Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C - 68C.
Pyorl K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [see comments]. Diabetes Care 1997; 20: 614–620.
Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 107C - 112C.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.
Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1237–1245.
Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313–321.
Sacks FM, Moye LA, Davis BR, et al. Relationship between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial. Circulation 1998; 97: 1446–1452.
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):23–33
a. MRCBHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trail. Lancet 2002;360(9326):7–22
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001; 285: 1711–1718.
Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000; 139: 577–583.
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
Kannel WB. Hypertension, hypertrophy, and the occurrence of cardiovascular disease. Am J Med Sci 1991; 302: 199–204.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.
Anonymous. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349–360.
Yusuf S, Anand S, Avezum A Jr, Flather M, Coutinho M. Treatment for acute myocardial infarction. Overview of randomized clinical trials. Eur Heart J 1996; 17 (Suppl. F): 16–29.
Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration [see comments] [published erratum appears in BMJ 1994 Jun 11;308(6943):1540]. BMJ 1994; 308: 81–106.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
Anonymous. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2: 57–66.
Goldstein S. Beta-blocking drugs and coronary heart disease. Cardiovasc Drugs Ther 1997;l 1(Suppl. 1 ): 219–225.
Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens Suppl 1995; 13: S11 - S17.
Madu EC, Reddy RC, Madu AN, Anyaogu C, Harris T, Fraker TD Jr. Review: the effects of antihypertensive agents on serum lipids. Am J Med Sci 1996; 312: 76–84.
Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92: 3132–3137.
Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997; 95: 2643–2651.
Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study [see comments]. N Engl J Med 1991; 325: 756–762.
Barrett-Connor E. The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas 1996; 23: 227–234.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.
Mosca L, Collins P, Herrington DM, et al. AHA Scientific Statement: hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503.
O’Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials after rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234–244.
Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 2000; 15: 416–421.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [see comments]. N Engl J Med 1998; 339: 229–234.
Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360 (9326): 2–3.
Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–419.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001; 8: 203–210.
Lonn E, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919–925.
Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593–1600.
Insull W The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 241: 317–325.
Qureshi A, Suri FK, Guterman LR, Hopkins N. Ineffective Secondary prevention in survivors of cardiovascular events in the US population. Report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161: 1621–1628.
Fonnarow GC, French WJ, Parsons LS, et al. Use of lipid lowering medication at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103: 38–44.
Braunstein JB, Cheng A, Fakhry C, et al. ABCs of cardiovascular disease risk management. Cardiol Rev 2001; 9: 96–105.
Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline. J Am Coll Cardiol 1999; 33: 2092–2197.
Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol 2000; 36: 668–673.
Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. JAm Coll Cardiol 2001; 38: 1581–1583.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Plutzky, J., Blumenthal, R.S. (2003). “Secondary Prevention” of Myocardial Infarction. In: Cannon, C.P. (eds) Management of Acute Coronary Syndromes. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-351-4_24
Download citation
DOI: https://doi.org/10.1007/978-1-59259-351-4_24
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-309-1
Online ISBN: 978-1-59259-351-4
eBook Packages: Springer Book Archive